Skip to main content

Table 2 Clinical features and follow up data of 41 extra-uterine and extra-ovarian mullerian adenosarcoma according to histological features

From: Primary extra-uterine and extra-ovarian mullerian adenosarcoma: case report and literature review

 

Total population

Endometriosis

P value

Overgrowth

P value

Heterologous sarcomatous differentiation

P value

 

n = 41 n (%)

No n = 16 n (%)

Yes n = 25 n (%)

 

No n = 32 n (%)

Yes n = 9 n (%)

 

No n = 37 n (%)

Yes n = 4 n (%)

 

Age (mean ± SD), years

44.5 ± 15.0

43.1 ± 15.8

45.5 ± 12.7

0.597

45.4 ± 13.9

41.4 ± 14.6

0.463

46.4 ± 13.0

27.5 ± 11.8

0.009

Size (mean ± SD), mm

12.2 ± 6.9

13.4 ± 8.3

11.0 ± 5.3

0.319

12.5 ± 6.7

11.0 ± 8.1

0.659

11.9 ± 6.8

14.7 ± 8.5

0.517

 Site

   

0.066

  

1

  

1

  Extra-genital

32 (78.0)

15 (93.8)

17 (68.0)

 

25 (78.1)

7 (77.8)

 

29 (78.4)

3 (75.0)

 

  Vagina

9 (22.0)

1 (6.2)

8 (32.0)

 

7 (21.9)

2 (22.2)

 

8 (21.6)

1 (25.0)

 

 Endometriosis

      

1

  

0.281

  No

16 (39.0)

–

–

–

13(40.6)

3 (33.3)

 

13 (35.1)

3 (75.0)

 

  Yes

25 (61.0)

–

–

–

19 (59.4)

6 (66.7)

 

24 (64.9)

1 (25.0)

 

 Overgrowth

   

1

     

1

  No

32 (78.0)

13 (81.3)

19(76.0)

 

–

–

 

29 (78.4)

3 (75.0)

 

  Yes

9 (22.0)

3 (18.7)

6 (24.0)

 

–

–

 

8 (21.6)

1 (25.0)

 

 Treatment

   

0.557

  

1

  

0.101

  Surgery

22 (53.7)

9 (56.3)

13 (52.0)

 

18 (56.3)

4 (44.4)

 

19 (51.4)

3 (75.0)

 

  Surgery + additional treatments

16 (39.0)

5 (31.2)

11 (44.0)

 

11 (34.4)

5 (55.6)

 

16 (43.2)

0 (0.0)

 

  No Surgery

3 (7.3)

2 (12.5)

1(4.0)

 

3 (9.4)

0 (0.0)

 

2 (5.4)

1 (25.0)

 

 Surgical Approach

   

0.345

  

1

  

0.327

  Complete resection

33 (80.5)

11 (68.8)

22 (88.0)

 

25 (78.1)

8 (88.9)

 

30 (81.1)

3 (75.0)

 

  Partial resection

5 (12.2)

3 (18.7)

2 (8.0)

 

4 (12.5)

1 (11.1)

 

5 (13.5)

0 (0.0)

 

  No surgery

3 (7.3)

2 (12.5)

1 (4.0)

 

3 (9.4)

0 (0.0)

 

2 (5.4)

1 (25.0)

 

 Lost in follow up

6 (14.6)

4

2

 

4

2

 

6

0

 

 Status at last follow up (35 patients)

   

0.002

  

0.843

  

0.278

  FOD

22 (62.9)

3 (25.0)

19 (82.6)

 

17 (60.7)

5 (71.4)

 

19 (61.3)

3 (75.0)

 

  AWD

4 (11.4)

3 (50.0)

1 (4.3)

 

4 (14.3)

0 (0.0)

 

3 (9.7)

1 (25.0)

 

  DOD

9 (25.7)

6 (25.0)

3 (13.0)

 

7 (25.0)

2 (28.6)

 

9 (29.0)

0 (0.0)

 

 Recurrence

18 (51.4)

9 (56.2)

9 (36.0)

0.184

13 (40.6)

5 (55.5)

0.447

15 (45.5)

3 (75.0)

0.340

 More than 1 recurrence

9 (25.7)

4 (28.6)

5 (21.7)

1

5 (17.9)

4 (57.1)

0.294

7 (18.9)

2 (50.0)

1

 Death patients OS (mean ± sd)

 

7.0 ± 5.7

46.3 ± 63.9

0.151

6.0 ± 4.0

16.7 ± 17.8

0.179

20.1 ± 37.8

–

*

 Patients with recurrence DFS (mean ± sd)

 

47.9 ± 63.6

28.0 ± 41.3

0.486

12.2 ± 11.4

11.4 ± 12.6

0.897

11.9 ± 12.1

11.6 ± 10.5

1

  1. AWD alive with disease, DOD died of disease, FOD free of disease
  2. *comparison was not possible, because no patients with heterologous sarcomatous differentiation dead during follow up